Key Highlights
● Topline data from the Phase 2 ALTITUDE-AD study are expected in late 2026.
● The trial enrolled 542 participants with early Alzheimer's disease.
● Cash and securities were $110.2 million at 30 June 2026, funding operations into early 2027.
● Second-quarter net loss was $32.7 million, or $0.45 per share.
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) is a clinical-stage biotechnology company whose common stock trades on Nasdaq under the symbol ABOS. Its second-quarter 2026 results, for the quarter ended 30 June 2026, were released on 12 August 2026.
The lead candidate is sabirnetug (ACU193), a humanised monoclonal antibody designed to target soluble amyloid beta oligomers, which are thought to be toxic species in Alzheimer's disease. It has Fast Track designation from the US Food and Drug Administration for early Alzheimer's disease. That designation speeds interaction with the regulator but does not signal approval or efficacy.
The ALTITUDE-AD trial
ALTITUDE-AD is a randomised, double-blind, placebo-controlled Phase 2 study, begun in 2024, in 542 participants with early Alzheimer's disease, meaning mild cognitive impairment or mild dementia due to the disease. Sites span the United States, Canada, the European Union and the United Kingdom. Participants receive intravenous sabirnetug every four weeks at 35 mg/kg or 50 mg/kg, or placebo, over 18 months. The primary endpoint is the integrated Alzheimer's Disease Rating Scale, with key secondary endpoints including the Clinical Dementia Rating Sum of Boxes, adverse events such as amyloid-related imaging abnormalities, and biomarkers.
The release also describes 180 participants per cohort; three such cohorts would total 540, slightly below the stated 542, so the cohort figure is probably approximate.
Financial position
All figures are in US dollars. Cash, cash equivalents and marketable securities were $110.2 million at 30 June 2026, down from $128.4 million at 31 March 2026, and management says this funds operations into early 2027. Research and development expense in the quarter was $27.8 million, against $37.1 million a year earlier, reflecting lower manufacturing, materials and contract research costs tied to the trial. General and administrative expense was $4.7 million. Net loss was $32.7 million, or $0.45 per share, compared with $41.0 million a year earlier. Total debt was $31.6 million, of which $19.7 million is short term. Shares outstanding rose to 72,314,714 from 60,575,369 at the end of 2025, partly after a private placement that contributed $35.4 million net in the six months.
Pipeline beyond the antibody
Acumen is also studying a subcutaneous formulation of sabirnetug using Halozyme's ENHANZE technology. In June 2026 it nominated two enhanced brain delivery candidates, ACU301 and ACU401, with JCR Pharmaceuticals as part of exercising a licence option. At the July Alzheimer's Association International Conference, the company reported that ACU401 achieved up to 40-fold greater frontal cortex exposure in non-human primates than native antibodies, with no haematological safety signals. It targets an investigational new drug submission for a lead candidate in mid-2027. These are preclinical results and carry the usual translation risk.
Why it matters, and the risks
The trial result is binary in effect: a convincing clinical signal could support further development and financing, while a miss would challenge the company's central programme. The cash runway into early 2027 is short relative to the time a later-stage study would require, so further funding or partnering may be needed whatever the outcome. Dilution is already visible in the share count. Safety, particularly amyloid-related imaging abnormalities, will be watched closely, as will how any benefit compares with approved amyloid antibodies.
A Late-2026 Readout With Timing Still Only an Expectation
Topline timing remains a company expectation that could change.






Please wait processing your request...